Education
About Us
Working with TipRanks
Follow Us
3D Medicines, Inc. (HK:1244)
:1244
RESEARCH TOOLSreports
1244 Stock Chart & Stats
Day’s Range― - ―
52-Week RangeHK$1.60 - HK$8.30
Previous CloseN/A
Volume120.00K
Average Volume (3M)648.95K
Market Cap
HK$1.86B
Enterprise ValueHK$25.83M
Total Cash (Recent Filing)HK$840.98M
Total Debt (Recent Filing)HK$237.62M
Price to Earnings (P/E)―
Beta1.73
Next Earnings
Aug 22, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.35
Shares Outstanding258,177,000
10 Day Avg. Volume1,087,637
30 Day Avg. Volume648,947
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
3D Medicines, Inc. News
1244 FAQ
What was 3D Medicines, Inc.’s price range in the past 12 months?
3D Medicines, Inc. lowest stock price was HK$1.60 and its highest was HK$8.30 in the past 12 months.
What is 3D Medicines, Inc.’s market cap?
3D Medicines, Inc.’s market cap is HK$1.86B.
When is 3D Medicines, Inc.’s upcoming earnings report date?
3D Medicines, Inc.’s upcoming earnings report date is Aug 22, 2025 which is in 13 days.
How were 3D Medicines, Inc.’s earnings last quarter?
3D Medicines, Inc. released its earnings results on Mar 31, 2025. The company reported -HK$0.35 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.35.
Is 3D Medicines, Inc. overvalued?
According to Wall Street analysts 3D Medicines, Inc.’s price is currently Overvalued.
Does 3D Medicines, Inc. pay dividends?
3D Medicines, Inc. does not currently pay dividends.
What is 3D Medicines, Inc.’s EPS estimate?
3D Medicines, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does 3D Medicines, Inc. have?
3D Medicines, Inc. has 258,177,000 shares outstanding.
What happened to 3D Medicines, Inc.’s price movement after its last earnings report?
3D Medicines, Inc. reported an EPS of -HK$0.35 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.266%.
Which hedge fund is a major shareholder of 3D Medicines, Inc.?
Currently, no hedge funds are holding shares in HK:1244
3D Medicines, Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
89.35%
12-Months-Change
Fundamentals
Return on Equity
-21.22%
Trailing 12-Months
Asset Growth
-17.72%
Trailing 12-Months
Company Description
3D Medicines, Inc.
3D Medicines, Inc. (1244) is a biotechnology company specializing in the research, development, and commercialization of advanced therapeutic solutions. Operating primarily in the pharmaceutical and healthcare sectors, the company focuses on innovative approaches to cancer treatment, leveraging cutting-edge technology to develop immuno-oncology drugs and personalized medicine solutions. Its core products include a range of therapeutic candidates designed to address unmet medical needs in oncology.
Technical Analysis
Transcenta Holding Limited
―
JW (Cayman) Therapeutics Co. Ltd.
―
TOT BIOPHARM International Co. Ltd.
―
Genor Biopharma Holdings Limited
―
Brii Biosciences Limited
―
Ownership Overview
―
Insiders
0.02%
Mutual Funds
― Other Institutional Investors
99.98% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---